Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan-Mar;6(1):e7.
doi: 10.2349/biij.6.1.e7. Epub 2010 Jan 1.

Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience

Affiliations

Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience

O Nawawi et al. Biomed Imaging Interv J. 2010 Jan-Mar.

Abstract

Purpose: This is a retrospective study to evaluate the results of our early experience of using doxorubicin eluting beads (DEB) to treat patients with early and intermediate hepatocellular carcinoma (HCC).

Material and methods: A cohort of 19 patients (84.2% male; 15.8% female; mean age 59.2 years ± 11.0; range, 32-80 years) with documented HCC of size 1.8-10cm (mean, 4.0cm ± 1.8 ) undergoing DEB transarterial chembolisation (TACE) was reviewed. All patients had at least one image examination (multiphase computed tomography or magnetic resonance imaging) after embolisation.

Results: A total of 32 procedures were performed. The objective response according to the European Association for the Study of the Liver criteria was 57.9% at 1-month, 42.8% at 6-month and 50.0% at 1-year follow up. There were 4 (21.1%) treatment-related complications (1 liver abscess, 2 pancreatitis and 1 tumour rupture) which resulted in 2 deaths. One death occurred 3 weeks after second embolisation, due to ruptured pancreatic pseudocyst, giving a 5.3% 30-day mortality rate. Another patient died 2 months after embolisation caused by tumour rupture. Eight patients received radiofrequency ablation after embolisation for residual or recurrent tumours. The 1-year survival rate in the DEB TACE only group was 80% while the 1- and 2-year survival rate in the group that received radiofrequency after DEB TACE was 85.7% and 100% respectively.

Conclusion: DEB TACE is safe and effective in select group of patients. Survival may be improved when combined with other treatment modality.

Keywords: Drug-eluting beads; doxorubicin; embolisation; hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multiphase CT in arterial phase showing a focal enhancing lesion in segment 6 (A). Angiogram before embolisation shows tumour (arrows) supplied by the branch of right hepatic artery (B). Multiphase CT in arterial phase 1 month after embolisation reveals complete disappearance of tumour, in keeping with complete response (C).
Figure 2
Figure 2
Multiphase CT in arterial phase showing a heterogenously enhancing lesion in the right lobe of liver (A). 1-month follow up CT in arterial phase shows tumour necrosis of most of the tumour with a small residual nodule at the periphery, in keeping with partial response (B).

References

    1. Brown DB, Geschwind JF, Soulen MC, et al. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006;17(2 Pt 1):217–23. - PubMed
    1. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;135(5):1164–71. - PubMed
    1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42. - PubMed
    1. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9. - PubMed
    1. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2 Pt 1):335–42. - PubMed

LinkOut - more resources